Vivozon Pharmaceutical Co., Ltd. (KOSDAQ: 082800)

Vivozon Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	5,326	7,987	2,351	13,799	64,331	57,331
Short-Term Investments	2,000	5,330	11,600	14,880	129.95	-
Trading Asset Securities	4,519	4,404	12,448	35,376	26,216	11,020
Cash & Short-Term Investments	11,845	17,721	26,400	64,055	90,677	68,351
Cash Growth	-3.10%	-32.88%	-58.79%	-29.36%	32.66%	109.81%
Accounts Receivable	-	13,187	8,847	10,712	10,746	4,535
Other Receivables	-	310.67	347.19	2,428	652.92	1,777
Receivables	-	14,148	9,694	13,163	11,509	6,312
Inventory	18,187	12,994	11,199	16,034	12,927	2,680
Prepaid Expenses	-	12.88	20.8	421.39	47.34	2.77
Other Current Assets	12,183	262.81	248.44	2,659	3,155	1,854
Total Current Assets	42,215	45,138	47,562	96,333	118,315	79,199
Property, Plant & Equipment	30,888	25,521	33,968	32,807	25,228	1,314
Long-Term Investments	90,443	91,484	95,242	45,857	48,493	16,602
Goodwill	-	-	-	-	19,341	-
Other Intangible Assets	4,318	4,631	5,574	8,612	26,158	114.58
Long-Term Accounts Receivable	-	0	-	-	-	-
Long-Term Deferred Tax Assets	-	-	-	3,431	2,372	-
Long-Term Deferred Charges	6,862	6,209	3,437	2,880	1,267	71.66
Other Long-Term Assets	1,002	660.93	1,006	653.97	4,866	67,343
Total Assets	175,728	173,647	187,074	194,471	248,159	164,654
Accounts Payable	-	10,632	6,152	6,622	6,332	5,495
Accrued Expenses	-	1,532	1,848	2,167	1,843	221.77
Short-Term Debt	38,321	39,996	52,572	67,993	90,952	41,328
Current Portion of Long-Term Debt	-	-	5,604	867.11	867.13	-
Current Portion of Leases	659.98	624.62	653.17	610.93	625.91	430.95
Current Unearned Revenue	-	3,504	3,685	3,685	3,685	-
Other Current Liabilities	26,662	8,490	8,746	7,078	7,265	6,916
Total Current Liabilities	65,644	64,779	79,261	89,023	111,570	54,391
Long-Term Debt	-	-	-	13,958	14,871	-
Long-Term Leases	774.99	994.18	1,481	685.36	1,107	7.27
Long-Term Deferred Tax Liabilities	923.51	923.51	927.93	1,823	5,596	-
Other Long-Term Liabilities	303.27	193.7	130.07	150.4	304.9	1,252
Total Liabilities	70,626	69,580	83,609	107,928	136,600	55,657
Common Stock	120,607	120,529	117,022	84,953	70,326	60,215
Additional Paid-In Capital	246,362	245,296	243,684	216,611	184,994	153,100
Retained Earnings	-262,566	-261,313	-257,365	-216,914	-147,709	-103,996
Treasury Stock	-13.12	-18.19	-	-	-	-
Comprehensive Income & Other	712.11	-427.4	125.39	469.82	192.97	-322.46
Total Common Equity	105,102	104,067	103,466	85,120	107,803	108,997
Minority Interest	-	-	-	1,422	3,757	-
Shareholders' Equity	105,102	104,067	103,466	86,542	111,560	108,997
Total Liabilities & Equity	175,728	173,647	187,074	194,471	248,159	164,654
Total Debt	39,756	41,615	60,310	84,115	108,424	41,766
Net Cash (Debt)	-27,911	-23,894	-33,910	-20,060	-17,747	26,585
Net Cash Growth	-	-	-	-	-	183.99%
Net Cash Per Share	-588.90	-500.74	-779.45	-615.13	-677.62	1265.08
Filing Date Shares Outstanding	47.52	47.21	46.81	33.98	28.13	24.09
Total Common Shares Outstanding	47.52	47.21	46.81	33.98	28.13	24.09
Working Capital	-23,429	-19,640	-31,699	7,310	6,745	24,808
Book Value Per Share	2211.85	2204.51	2210.40	2504.91	3832.28	4525.32
Tangible Book Value	100,784	99,436	97,892	76,508	62,304	108,882
Tangible Book Value Per Share	2120.97	2106.41	2091.33	2251.47	2214.83	4520.56
Land	6,037	6,037	6,037	6,183	6,183	-
Buildings	3,389	6,678	6,557	7,886	8,487	-
Machinery	12,814	23,401	20,015	22,216	23,749	1,275
Construction In Progress	7,175	1,943	12,132	9,142	83.06	-

Source: S&P Capital IQ. Standard template. Financial Sources.